Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

NCT02596334 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

158

Enrollment

OTHER

Sponsor class

Stopped 5 patients on tivicay had virological failure

Conditions

HIV

Interventions

DRUG: dolutegravir 50mg +abacavir 600mg +lamivudine 300mg
DRUG: dolutegravir

Sponsor

Centre Hospitalier Régional d'Orléans